Preladenant
Encyclopedia
Preladenant is a drug developed by Schering-Plough
which acts as a potent and selective antagonist
at the adenosine A2A receptor
. It is being researched as a potential treatment for Parkinson's disease
. Positive results were reported in Phase II clinical trials in humans.
Schering-Plough
Schering-Plough Corporation was a United States-based pharmaceutical company. It was founded in 1851 by Ernst Christian Friedrich Schering as Schering AG in Germany. In 1971, the Schering Corporation merged with Plough to form Schering-Plough. On November 4, 2009 Merck & Co...
which acts as a potent and selective antagonist
Receptor antagonist
A receptor antagonist is a type of receptor ligand or drug that does not provoke a biological response itself upon binding to a receptor, but blocks or dampens agonist-mediated responses...
at the adenosine A2A receptor
Adenosine A2A receptor
The adenosine A2A receptor, also known as ADORA2A, is an adenosine receptor, but also denotes the human gene encoding it.-Structure:This protein is a member of the G protein-coupled receptor family which possess seven transmembrane alpha helices...
. It is being researched as a potential treatment for Parkinson's disease
Parkinson's disease
Parkinson's disease is a degenerative disorder of the central nervous system...
. Positive results were reported in Phase II clinical trials in humans.